Anti-her4 antibodies and methods of making and using the same

By preparing antibodies or antigen-binding fragments that specifically bind to HER4 extracellular domain III, the lack of precision in the treatment of HER4-related diseases in existing technologies has been solved. This has enabled the inhibition of HER4 receptor dimerization and downstream signal transduction, providing a variety of treatment and diagnostic methods.

CN119823276BActive Publication Date: 2026-06-05LATTICON (SUZHOU) BIOPHARMACEUTICALS CO LTD
View PDF 43 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN Β· China
Patent Type
Patents(China)
Current Assignee / Owner
LATTICON (SUZHOU) BIOPHARMACEUTICALS CO LTD
Filing Date
2024-10-10
Publication Date
2026-06-05

AI Technical Summary

Technical Problem

Existing technologies make it difficult to develop antibodies that can specifically bind to HER4 and block its ligand-induced dimerization and downstream signal transduction pathways, resulting in a lack of precision in the treatment of HER4-related diseases.

Method used

An antibody or its antigen-binding fragment that specifically binds to the extracellular domain III of HER4 is provided. It is prepared by methods such as hybridoma technology and phage display technology and can block the dimerization of the HER4 receptor and downstream signal transduction pathways, including NRG-1-induced HER2/HER4 receptor dimerization.

Benefits of technology

It enables precise treatment of HER4-related diseases by inhibiting HER4 receptor dimerization and downstream signal transduction, and provides a variety of drug combinations and treatment methods, including bispecific molecules and immune conjugates, which enhance the therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005078377280000031
    Figure BDA0005078377280000031
  • Figure BDA0005078377280000041
    Figure BDA0005078377280000041
  • Figure BDA0005078377280000091
    Figure BDA0005078377280000091
Patent Text Reader

Abstract

The present application provides an anti-HER4 antibody or antigen-binding fragment thereof. The present application further provides a bispecific molecule or a multispecific molecule comprising the antibody or antigen-binding fragment thereof, an immunoconjugate, and a nucleic acid molecule encoding the antibody or antigen-binding fragment thereof, a vector and host cell comprising the nucleic acid molecule. The present application also provides a method of preparing the antibody or antigen-binding fragment thereof, a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, and a method and use of the antibody or antigen-binding fragment thereof, or a pharmaceutical composition thereof in treating a disease, which provides a candidate specific antibody drug for the treatment and / or prevention of diseases or disorders related to HER4.
Need to check novelty before this filing date? Find Prior Art